Dataset Information

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

ABSTRACT:

Objectives

This study aimed to provide real-world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death.

Methods

The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date.

Results

Data from 786 patients were reviewed. At the time of death, 37% of patients were receiving active treatment, 12% were in a treatment-free interval and 51% were receiving only supportive care. Death before and during active first-line treatment was not uncommon (6% and 24% of patients, respectively) but these deaths were often not solely due to disease progression; factors such as renal failure and infection frequently played a role (in 30% and 20% of patients at first-line, respectively). Most deaths at later lines were due to progressive disease. Cox model results suggested that early deaths were associated with advanced disease stage, high-risk cytogenetics and poor response and relapse profiles.

Conclusions

These real-world data could be used to help develop strategies for improving survival in patients with MM and to support management tailored to the stage of disease.

SUBMITTER: Mohty M

PROVIDER: S-EPMC6851592 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Mohty Mohamad M Cavo Michele M Fink Leah L Gonzalez-McQuire Sebastian S Leleu Henri H Mateos Maria-Victoria MV Raab Marc S MS Schoen Paul P Yong Kwee K

European journal of haematology 20190618 2

<h4>Objectives</h4>This study aimed to provide real-world data on the characteristics and treatment of patients with multiple myeloma (MM) at the time of death.<h4>Methods</h4>The study was a retrospective patient chart review across France, Germany, Italy, Spain and the UK during 2016, and included patients who had died in the 3 months before the index date.<h4>Results</h4>Data from 786 patients were reviewed. At the time of death, 37% of patients were receiving active treatment, 12% were in a ...[more]

PMID: 31112311

Similar Datasets

Project description:BACKGROUND:Bone complications (pathologic fracture, spinal cord compression, surgery to bone and radiation to bone) are a common problem in patients with multiple myeloma (MM). We set out to provide insights into the real-world burden of bone complications in patients with newly diagnosed MM (NDMM). METHODS:We conducted a retrospective review of medical charts of patients with NDMM whose disease had progressed following first-line treatment in the 3?months before data collection in 2016 in five European countries (France, Germany, Italy, Spain and the United Kingdom). RESULTS:The aggregated study population included 813 patients. Bone pain commonly led to MM diagnosis (63%) and 74% of all patients had two or more bone lesions at initiation of first-line treatment. Furthermore, 26% of patients experienced a new bone complication between MM diagnosis and disease progression following first-line treatment, despite 75% of individuals receiving bisphosphonates. Most bone complications (52%) occurred in the period before initiation of first-line treatment (mean duration: 2.3?months) and more than half of patients (56%) who experienced a new bone complication were hospitalised. Analgesics were used more frequently in patients with bone complications than in those without them (76% vs 50%, respectively). Furthermore, 51% of patients had renal impairment by the time first-line treatment was started. Overall, 25% of patients did not receive bisphosphonates for prevention of bone complications and one in four of those with renal impairment at initiation of first-line treatment did not receive bisphosphonates. CONCLUSIONS:Bone complications are common in patients with NDMM. They are frequently associated with hospitalization and analgesic use. Data from this study, conducted in the era of novel anti-myeloma therapies and before the approval of denosumab for use in patients with MM, suggest that although most patients (75%) received bisphosphonates, use of anti-resorptive therapy for prevention of bone complications may be suboptimal in patients with NDMM, irrespective of renal function.

Dataset Information

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Objectives

Methods

Results

Conclusions

Publications

Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets